In vitro antimicrobial evaluation of Coated VICRYL* Plus Antibacterial Suture (coated polyglactin 910 with triclosan) using zone of inhibition assays.
BACKGROUND
In this study, coated polyglactin 910 suture with triclosan was evaluated for its ability to inhibit the growth of wild-type and methicillin-resistant Staphylococcus aureus and S. epidermidis using several in vitro models.


METHODS
In the standard experimental procedure, sterile sutures were inoculated with bacteria, plated in semisolid culture media, incubated for 24 h, and examined for zones of inhibition surrounding the sutures. Sutures were pretreated by several methods prior to inoculation, these included: 24-h aqueous immersion, serial 7-day aqueous immersion, knotting, and passage through subcutaneous and fascial tissue. Sutures were also compared to determine if suture diameter had an effect on the zone of inhibition.


RESULTS
Coated polyglactin 910 suture with triclosan inhibited growth of test organisms consistently over a range of suture diameters and treatment conditions. The antibacterial effect was robust and did not diminish when sutures were placed in an aqueous environment for up to 7 days. Knotted suture with triclosan inhibited bacterial colonization after replicate inoculation. The bacteria-free zone surrounding each knotted suture had a volume of 14.5 cm(3) for S. epidermidis and 17.8 cm(3) for S. aureus. Coated polyglactin 910 suture with triclosan continued to produce zones of inhibition after five and 10 passes through fascia and subcutaneous tissue.


CONCLUSIONS
These data support the conclusion that coated polyglactin 910 suture with triclosan provides antimicrobial effect sufficient to prevent in vitro colonization by S. aureus and S. epidermidis.
Rothenburger
Stephen
S
Ethicon, Inc, Somerville, New Jersey 08876, USA. srothenb@ethus.jnj.com
Spangler
Daniel
D
Bhende
Shubhangi
S
Burkley
Daniel
D
D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D001681:Biological Assay; D020099:Coated Materials, Biocompatible / Q000494:pharmacology* / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D003260:Contact Inhibition / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D016106:Methicillin Resistance; D011098:Polyglactin 910 / Q000494:pharmacology* / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development; D013212:Staphylococcus epidermidis / Q000187:drug effects* / Q000254:growth & development; D013997:Time Factors; D014260:Triclosan / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*
D000891:Anti-Infective Agents, Local; D020099:Coated Materials, Biocompatible; D011098:Polyglactin 910; D014260:Triclosan